Resource utilization and cost of episodes of febrile neutropenia in children with acute leukemias and lymphomas

Supportive Care in Cancer

Volumn 11, Issue 6, 2003, Pages 356-361

  Costa, V C ^a   Ferraz, M B ^a   Petrilli, A S ^b   Pereira, C A ^b   Rogerio, J W ^b  

^a Paulista Center for Health Economics   (Brazil)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Acute leukemia; Acute lymphoma; Cost; Febrile neutropenia; Pediatrics

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ARTICLE; BODY TEMPERATURE; BRAZIL; CELL COUNT; CHILD; FEBRILE NEUTROPENIA; FEMALE; HEALTH CARE COST; HEALTH CARE PLANNING; HEALTH CARE UTILIZATION; HODGKIN DISEASE; HUMAN; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; NEUTROPHIL; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROGNOSIS;

EID: 0037700223     PISSN: 09414355     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00520-002-0429-1     Document Type: Article

References (15)

1. Agaoglu L, Devecioglu O, Karakas Z, et al (2001) Cost-effectiveness of cefepime + netilmicin or ceftazidime + amikacin or meropenem monotherapy in febrile neutropenic children with malignancy in Turkey. J Chemother 13:281-287
2. Ariffin H, Arasu A, Mahfuzah M, Ariffin WA, Chan LL, Lin HP (2001) Single-daily ceftriaxone plus amikacin versus thrice-daily ceftazidime plus amikacin as empirical treatment of febrile neutropenia in children with cancer. J Pediatr Child Health 37:38-43
3. Brasindice (2000) Pharmaceutical guide. Andrei, Brasilia
4. Brazilian Medical Association (1966) List of medical procedures. Brazilian Medical Association, Brasilia
5. Castagnola E, Paola D, Giacchino R, Rossi R, Viscoli C (1998) Economic aspects of empiric antibiotic therapy for febrile neutropenia in children with cancer. Support Care Cancer 6:524-528
6. Dietrich ES, Patz E, Frank U, Daschner FD (1999) Cost-effectiveness of ceftazidime or imipenem/cilastatin versus ceftriaxone + aminoglycoside in the treatment of febrile episodes in neutropenic cancer patients in Germany. Infection 27:23-31
7. Dranitsaris G (1999) Clinical and economic considerations of empirical antibacterial therapy of febrile neutropenia in cancer. Pharmacoeconomics 16:343-353
8. Harbarth S, Beeler I, Viot M, Szucs TD (1999) Resource implications of febrile neutropenia in cancer patients - an international collaborative study. Support Care Cancer 7:343-346
9. Hughes WT, Armstrong D, Bodey GP, et al (1997) Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. J Infect Dis 25:551-573
10. Kairos Pharmaceutical Journal (in Portuguese) (2000) issue 141
11. Leese B (1993) The costs of treating febrile neutropenia in six U.K. hospitals. Eur J Cancer 29 [A] S7:S15-S18
12. Leese B, Collin R, Clark DJ (1994) The costs of treating febrile neutropenia in patients with malignant blood disorders. Pharmacoeconomics 6:233-239
13. Paladino JA, Fong DA, Forrest A, Ramphal R (2000) Cost effectiveness of cephalosporin monotherapy and aminoglycoside / ureidopenicillin combination therapy - for the treatment of febrile episodes in neutropenic patients. Pharmacoeconomics 18:369-381
14. Petrilli AS, Melaragno R, Barros KVT, et al (1993) Fever and neutropenia in children with cancer: a therapeutic approach related to the underlying disease. Pediatr Infect Dis J 12:916-921
15. Torfs K (1997) Economic evaluation of cancer treatment strategies. Eur J Cancer 33 [S4]:S35-S39